ReviewNature reviews. Cancer2026
N
Abstract readReview
In one paragraph
Review in Nature reviews. Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- RBM15 in leukemogenesis: an emerging regulator at the interface of RNA biology and hematopoiesis.Trends in cancer · 2026Review
- Targeting MYC-Driven Cancers: From Oncogenic Addiction to Therapeutic Vulnerability.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- m6A-Driven Pexophagy Triggers Placental Ferroptosis to Impair Fetal Growth Upon Environmental Stress.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Targeting NAT10 Activates Tumor-Intrinsic Immunity and Suppresses Tumor Progression in Head and Neck Squamous Cell Carcinoma.bioRxiv : the preprint server for biology · 2026Article
- RNA methyltransferase 3 drives pancreatic acinar cell carcinoma growth and is a therapeutic target.Signal transduction and targeted therapy · 2026Article
- Emerging roles of mJournal of assisted reproduction and genetics · 2026Review
- Pharmacological METTL3 inhibition attenuates HIV-1 latency reversal in CD4Antimicrobial agents and chemotherapy · 2026Article
- N7-Methylguanosine Modification in Colorectal Cancer: Molecular Insights and Clinical Implications.International journal of molecular sciences · 2026Review
- Targeted delivery of TGF-β inhibitor via LHRH-NanoTi reverses the NAT10/ac4C-mediated cisplatin-induced immunosuppressive tumor microenvironment in ovarian cancer.Journal of nanobiotechnology · 2026Article
- Targeting mAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Integrated pan cancer analysis with breast cancer validation identifies SEC13 homolog as prognostic biomarker and immunotherapy target.Scientific reports · 2026Article
- Elevated mBMC cancer · 2026Article
- Pharmacological METTL3 inhibition attenuates HIV-1 latency reversal in CD4bioRxiv : the preprint server for biology · 2026Article
- Molecular Insights into Widespread Pseudouridine RNA Modifications: Implications for Women's Health and Disease.Biology · 2026Review
- Methyltransferase-Like 3 Inhibition-Activated cGAS/STING Axis Enhances Immunotherapy and Poly(ADP-Ribose) Polymerase Inhibitor Sensitivity in Lung Adenocarcinoma.Research (Washington, D.C.) · 2026Article
- m6A-Targeted Cancer Therapy: Molecular Targets, Inhibitors, and Nanodelivery Strategies.International journal of nanomedicine · 2026Review
- Decoding the tumor-aging axis: from bench to clinical.Frontiers in immunology · 2026Review
- Diverse roles of YTHDC1 in chromatin and blood cancers.Frontiers in genetics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Hanzhi LuoMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Hanzhi.luo@fccc.edu.ORCID http://orcid.org/0000-0002-4906-967X
Michael G KharasMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. kharasm@mskcc.org.ORCID http://orcid.org/0000-0002-1165-6991
Samie R JaffreyDepartment of Pharmacology, Weill Cornell Medicine, New York, NY, USA. srj2003@med.cornell.edu.ORCID http://orcid.org/0000-0003-3615-6958
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MCenter for Multi-Scale Analysis of the Human EpitranscriptomeRM1HG011563 · NHGRI · WEILL MEDICAL COLL OF CORNELL UNIV · PI SAMIE R JAFFREY, Kathryn D Meyer · 2021 to 2026
$22.2MNew mechanisms and technologies for understanding post-transcriptional gene regulation in neuronsR35NS111631 · NINDS · WEILL MEDICAL COLL OF CORNELL UNIV · PI SAMIE R JAFFREY · 2019 to 2026
$8.6MMechanisms of epitranscriptomic regulation in cancerR01CA186702 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI SAMIE R JAFFREY, Michael Kharas · 2014 to 2026
$8.0MUncovering the role for MSI2 network in hematopoietic stem cellsR01DK101989 · NIDDK · SLOAN-KETTERING INST CAN RESEARCH · PI Michael Kharas, Vijay Ganesh Sankaran · 2014 to 2026
$6.2MCharacterizing the MSI2 network in leukemiaR01CA193842 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI KHARAS, MICHAEL · 2015 to 2025
$4.1MIdentification of therapeutic targets for leukemia stem cells in AML-iPSC modelsR01CA225231 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KHARAS, MICHAEL, PAPAPETROU, EIRINI · 2018 to 2022
$3.2MInterrogation of the oxidative-stress-induced leukemia program in vivo usingmetabolic imagingR01CA283578 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Kayvan R Keshari, Michael Kharas · 2023 to 2026
$3.0MMolecular and genetic analysis of novel Slicer-dependent miRNA pathways in bloodR01HL135564 · NHLBI · SLOAN-KETTERING INST CAN RESEARCH · PI KHARAS, MICHAEL, LAI, ERIC C · 2017 to 2020
$2.9MUnderstanding resistance mechanisms to protein arginine methyltransransferase Inhibitors in LymphomaR01CA274249 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Michael Kharas · 2023 to 2026
$2.8MDefining the molecular basis controlling hematopoietic stem cell symmetric and asymmetric divisionsR00DK128602 · NIDDK · RESEARCH INST OF FOX CHASE CAN CTR · PI Hanzhi Luo · 2024 to 2026
$747kDefining the molecular basis controlling hematopoietic stem cell symmetric and asymmetric divisions -supplementK99DK128602 · NIDDK · SLOAN-KETTERING INST CAN RESEARCH · PI LUO, HANZHI · 2021 to 2023
$235kNCI NIH HHS P30 CA008748NCI NIH HHS R01 CA186702NCI NIH HHS R01 CA193842NCI NIH HHS R01 CA225231NCI NIH HHS R01 CA274249NCI NIH HHS R01 CA283578NHGRI NIH HHS RM1 HG011563NHLBI NIH HHS R01 HL135564NIDDK NIH HHS K99 DK128602NIDDK NIH HHS R00 DK128602NIDDK NIH HHS R01 DK101989NINDS NIH HHS R35 NS111631
Abstract
N
Indexed as
AdenosineNeoplasmsAnimalsGene Expression Regulation, NeoplasticHumansMethyltransferasesRNA, MessengerRNA Processing, Post-TranscriptionalTumor MicroenvironmentAdenosineMethyltransferasesMETTL3 protein, humanN-methyladenosineRNA, Messenger
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.